Less Ads, More Data, More Tools Register for FREE

Pin to quick picks4basebio Plc Regulatory News (4BB)

Share Price Information for 4basebio Plc (4BB)

Share Price is delayed by 15 minutes
Get Live Data
525.00    0.00 (0.00%)
Bid:
500.00
Ask:
550.00
Spread: 50.00 (10.00%)
Market Cap: £81.30m
4BB Live PriceLast checked at - London Stock Exchange

Intraday 4basebio Plc Share Chart

Holding(s) in Company

19 Feb 2021 17:35

4basebio UK Societas - Holding(s) in Company

4basebio UK Societas - Holding(s) in Company

PR Newswire

London, February 19

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:4basebio UK Societas
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rightsx
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
NameWilhelm K. T. Zours
City and country of registered office (if applicable)Heidelberg, Germany
4. Full name of shareholder(s) (if different from 3.)v
NameDELPHI Unternehmensberatung Aktiengesellschaft
City and country of registered office (if applicable)Heidelberg, Germany
5. Date on which the threshold was crossed or reachedvi:17/02/2021
6. Date on which issuer notified (DD/MM/YYYY):17/02/2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached20.27%-20.27%12,317,473
Position of previous notification (if applicable)---

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)Number of voting rightsix% of voting rights
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BLD8ZL39-2,496,933-20.27%
SUBTOTAL 8. A2,496,93320.27%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights
N/A
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights% of voting rights
N/A
SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)X
Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Wilhelm K. T. Zours
DELPHI Unternehmensberatung Aktiengesellschaft5.18%5.18%
Deutsche Balaton Aktiengesellschaft4.11%4.11%
Sparta AG10.97%10.97%
10. In case of proxy voting, please identify:
Name of the proxy holderN/A
The number and % of voting rights heldN/A
The date until which the voting rights will be heldN/A
11. Additional informationxvi
Wilhelm K. T. Zours controls circa 48% of 4basebio AG, who in turn holds 30% of the voting rights of 4basebio UK Societas.

Place of completionHeidelberg, Germany
Date of completion19/02/2021
Date   Source Headline
8th Jul 20267:00 amPRNDirector Appointment
30th Jun 20265:37 pmPRNResult of AGM & Issue of Options
16th Jun 20267:00 amPRNNotice of Investor Presentation
15th Jun 20267:00 amPRN4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
5th Jun 20267:00 amPRNNotice of Annual General Meeting
22nd May 20269:10 amPRNDirector Dealing
20th May 20267:02 amPRNFinal Results and Notice of AGM
20th May 20267:00 amPRN4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial
14th May 20267:00 amPRNAppointment of Chief Financial Officer and Board Changes
11th May 20267:00 amPRN4basebio Launches Enzymatic ssDNA Platform
31st Mar 20267:00 amPRNLease of Manufacturing Facility
12th Mar 20267:00 amPRNAppointment of COO
3rd Mar 20267:00 amPRNAppointment of CCO
16th Feb 20267:00 amPRNDirector Dealing
11th Feb 20263:58 pmPRNDirector Dealing
10th Feb 20267:00 amPRNLeadership Changes
27th Oct 20257:00 amPRNSynthetic opDNA® utilised in Phase I/II US clinical trials
10th Oct 202511:30 amPRNResult of Extraordinary General Meeting
30th Sep 20254:20 pmPRNDirector Dealing
29th Sep 20257:00 amPRNHalf-year Report
22nd Jul 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
8th Jul 202510:30 amPRNDirector Appointment, Board Change
3rd Jul 20257:00 amPRNHolding(s) in Company
3rd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNHolding(s) in Company
27th Jun 20256:05 pmPRNResult of AGM
25th Jun 20257:00 amPRNExercise of Options
17th Jun 20257:00 amPRNHolding(s) in Company
17th Jun 20257:00 amPRNHolding(s) in Company
27th May 20257:00 amPRNFinal Results and Notice of AGM
4th Apr 202512:00 pmPRNDirector Dealing
2nd Apr 20257:00 amPRN4basebio Receives GMP Licence for its UK DNA Manufacturing Facility
25th Mar 202510:15 amPRNHolding(s) in Company
14th Mar 20257:00 amPRNRBC Capital Markets initiates research coverage
7th Mar 20257:00 amPRNEmployee Long Term Incentive Plan and Issue of Equity
3rd Mar 20254:37 pmPRNDirector's Dealing
8th Jan 20257:00 amPRNAppointment of Chief Commercial Officer
17th Dec 20247:00 amPRNDirectorate Change
29th Nov 202412:30 pmPRNDirector's Dealing
19th Nov 20242:15 pmPRNDirector's Dealing
15th Nov 20245:31 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company
15th Nov 20245:30 pmPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.